ArticleMethods (San Diego, Calif.)2014
Antibody conjugation via one and two C-terminal selenocysteines.
Article in Methods (San Diego, Calif.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Disulfide re-bridging reagents for single-payload antibody-drug conjugates.Chemical communications (Cambridge, England) · 2023Article
- Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology.Bioconjugate chemistry · 2023Article
- Template directed synthesis of antibody Fc conjugates with concomitant ligand release.Chemical science · 2022Article
- Affinity-Based Methods for Site-Specific Conjugation of Antibodies.Bioconjugate chemistry · 2021Review
- Considerations for the Design of Antibody-Based Therapeutics.Journal of pharmaceutical sciences · 2020Review
- [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019Article
- Stable and Potent Selenomab-Drug Conjugates.Cell chemical biology · 2017Article
- Spontaneous Isopeptide Bond Formation as a Powerful Tool for Engineering Site-Specific Antibody-Drug Conjugates.Scientific reports · 2016Article
- Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts.Organic & biomolecular chemistry · 2016Article
- Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.Bioconjugate chemistry · 2015Article
- An Umpolung Approach for the Chemoselective Arylation of Selenocysteine in Unprotected Peptides.Journal of the American Chemical Society · 2015Article
- Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.The AAPS journal · 2015Review
- Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.Cancer research · 2014Article
- Improving the serum stability of site-specific antibody conjugates with sulfone linkers.Bioconjugate chemistry · 2014Article
- Chemically programmed antibodies.Trends in biotechnology · 2014Review
- In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds.BMB reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Conventional antibody conjugation methods generate antibody-drug conjugates that are heterogeneous mixtures with undefined stoichiometry and variable pharmacokinetic and pharmacodynamic properties. We have previously described a strategy to generate site-specific antibody conjugates by genetic engineering of an antibody with a single C-terminal selenocysteine, the 21st natural amino acid, which displays unique chemical reactivity allowing selective conjugation in the presence of all other natural amino acids. In the present work, we describe a method for expanding this technology to higher drug-to-antibody ratios by genetically engineering an antibody with two C-terminal selenocysteines. Both selenocysteines effectively conjugate to a fluorescent iodoacetamide derivative and the resulting conjugate fully retains its antigen binding capability. Our method provides a platform for creating stoichiometrically defined antibody-drug conjugates for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.